Stockscreener 앱 받기
51.89
5.67%
2.785
전일 마감가:
$49.10
열려 있는:
$49.18
하루 거래량:
80,927
Relative Volume:
1.32
시가총액:
$142.82M
수익:
$697.00K
순이익/손실:
$-37.19M
주가수익비율:
-1.3766
EPS:
-37.6952
순현금흐름:
$-29.34M
1주 성능:
+2.90%
1개월 성능:
-8.43%
6개월 성능:
-37.78%
1년 성능:
-90.34%
1일 변동 폭
$49.02
$53.25
1주일 범위
$46.50
$53.25
52주 변동 폭
$7.26
$543.38
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
51.89 | 142.82M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Craig Hallum | Buy |
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
SPRB Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential By Investing.com - Investing.com Australia
Spruce Biosciences (SPRB) Reports Promising Long-Term Results fo - GuruFocus
Jones Trading initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com UK
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B Presented at the 18th International MPS Symposium - Investing News Network
Spruce says long-term TA-ERT data presented at MPS Symposium - TipRanks
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation - Investing.com
Spruce Biosciences stock rises on MPS IIIB data, analyst initiation By Investing.com - Investing.com Canada
Spruce Biosciences (SPRB) Reports Promising Long-Term Results for Enzyme Therapy - GuruFocus
Spruce presents six-year data on MPS IIIB therapy candidate By Investing.com - Investing.com South Africa
Spruce presents six-year data on MPS IIIB therapy candidate - Investing.com
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire
SPRB News | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Biosciences (SPRB) Edges Lower Amid Consolidation PhaseChart Pattern Alerts - newsline.com
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spire Global, Inc. (SPIR) Is Up 7.94% in One Week: What You Should Know - Yahoo Finance
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $150 - Moomoo
SPRB Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright - TipRanks
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium - BioSpace
Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium - TradingView
Spruce Biosciences to Participate in Upcoming Conferences in June 2026 - BioSpace
Spruce Biosciences to Participate in Upcoming Conferences in June - Investing News Network
Spruce Biosciences Stockholders Approve Directors and Annual Say-on-Pay - The Globe and Mail
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $230 - Moomoo
Oppenheimer lowers Spruce Biosciences stock price target to $230 By Investing.com - Investing.com South Africa
Oppenheimer lowers Spruce Biosciences stock price target to $230 - Investing.com
Spruce Biosciences (SPRB) director granted 1,700 stock options at 52.70 - Stock Titan
Director Camilla V. Simpson awarded 1,700 SPRB options at $52.70 strike - Stock Titan
Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) grants director 1,700 options - Stock Titan
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
Spruce Biosciences (SPRB) 2026 annual meeting and say-on-pay votes - Stock Titan
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Spruce Biosciences Inc (SPRB) Stock Price, Quote, News & History - Benzinga
SPRB: Directors elected, all proposals approved, and strategic plans funded for regulatory milestones - TradingView
SPRB: All proposals passed, with updates on financing, manufacturing, and regulatory milestones shared - TradingView
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
Is Spruce Biosciences (SPRB) Overvalued After Q1 2026 EPS Beat? - GuruFocus
Citadel entities, Kenneth Griffin hold ~5.1% of Spruce Biosciences (SPRB) - Stock Titan
Alyeska Group (SPRB) discloses 61,670-share position, 4.49% of float - Stock Titan
Leerink Partners Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $120 - Moomoo
Squadron entities report 12,200 SPRB shares (0.9%) — SPRB - Stock Titan
Wellington Group discloses 48,796 shared dispositive shares in Spruce Biosciences (NASDAQ: SPRB) - Stock Titan
SPRB Maintains by Citizens -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences 1Q Research and Development Expenses $7.6M >SPRB - Moomoo
Spruce Biosciences, Inc. Stock 12‑Month Price Target Cut to $178.6, Implies 210% Upside - TradingView
Spruce Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Spruce Biosciences price target lowered to $150 from $170 at Citizens - TipRanks
Citizens lowers Spruce Biosciences stock price target on model update By Investing.com - Investing.com Nigeria
Citizens lowers Spruce Biosciences stock price target on model update - Investing.com
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):